Molecular Docking Analysis of Docetaxel Analogues As Duel Lipocalin 2 Inhibitors

Overview

Journal Bioinformation

Specialty Biology

Date 2020 Sep 5

PMID 32884206

Citations 1

Authors

Rajagopal Ponnulakshmi

Umapathy Vidhya Rekha

Ramakrishnan Padmini

Srinivasan Perumal

Radhakrishnan Saravanan

Veeraraghavan Vishnupriya

Periyasamy Vijayalakshmi

Jayaraman Selvaraj

Affiliations

Soon will be listed here.

Abstract

Lipocalin 2 (Lcn2, also called as neutrophil gelatinase-associated lipocalin) is a member of the lipocalin family and a known target for breast cancer. Therefore, it is of interest to use Docetaxel as a scaffold to design molecules with improved efficiency from naturally derived phytochemicals. We document 10 analogues (4Deacetyltaxol, 7Acetyltaxol, Cabazitaxel, Cephalomannine, Docetaxal, Deacetyltaxol, Docetaxeltrihydrate, Ortataxel, Paclitaxel, Taxoline) having optimal binding with Lipocalin 2 in comparison with Docetaxel. This data is highly useful for consideration in the design and development of drugs for breast cancer.

Citing Articles

Identification of Novel LCN2 Inhibitors Based on Construction of Pharmacophore Models and Screening of Marine Compound Libraries by Fragment Design.

Zheng N, Li X, Zhou N, Luo L Mar Drugs. 2025; 23(1).

PMID: 39852526 PMC: 11767183. DOI: 10.3390/md23010024.

Comparative analysis of Doxycycline and Ayurvedic herbs to target metastatic breast cancer: An approach.

Balkrishna A, Mittal R, Malik R, Verma H, Mehra K, Chaturvedi H Biomedicine (Taipei). 2024; 14(2):74-79.

PMID: 38939099 PMC: 11204128. DOI: 10.37796/2211-8039.1448.

References

Nabholtz J, Senn H, Bezwoda W, Melnychuk D, Deschenes L, Douma J . Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999; 17(5):1413-24. DOI: 10.1200/JCO.1999.17.5.1413. View

Viau A, Karoui K, Laouari D, Burtin M, Nguyen C, Mori K . Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010; 120(11):4065-76. PMC: 2964970. DOI: 10.1172/JCI42004. View

Rampogu S . Role of breast cancer inhibitors on diabetes mellitus- an in silico approach. J Diabetes Metab Disord. 2015; 14:11. PMC: 4372166. DOI: 10.1186/s40200-015-0138-1. View

Schneidman-Duhovny D, Inbar Y, Polak V, Shatsky M, Halperin I, Benyamini H . Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins. 2003; 52(1):107-12. DOI: 10.1002/prot.10397. View

Jones S, Erban J, Overmoyer B, Budd G, Hutchins L, Lower E . Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23(24):5542-51. DOI: 10.1200/JCO.2005.02.027. View

Qian S, Waldron L, Choudhary N, Klevit R, Chazin W, Patterson C . Engineering a ubiquitin ligase reveals conformational flexibility required for ubiquitin transfer. J Biol Chem. 2009; 284(39):26797-802. PMC: 2785368. DOI: 10.1074/jbc.M109.032334. View

Asimakopoulou A, Weiskirchen S, Weiskirchen R . Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy. Front Physiol. 2016; 7:430. PMC: 5037186. DOI: 10.3389/fphys.2016.00430. View

Leng X, Wu Y, Arlinghaus R . Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol. 2010; 226(2):309-14. DOI: 10.1002/jcp.22403. View

Moschen A, Adolph T, Gerner R, Wieser V, Tilg H . Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. Trends Endocrinol Metab. 2017; 28(5):388-397. DOI: 10.1016/j.tem.2017.01.003. View

10.

Clark R, Lee S . Anticancer Properties of Capsaicin Against Human Cancer. Anticancer Res. 2016; 36(3):837-43. View

11.

Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D . Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999; 17(8):2341-54. DOI: 10.1200/JCO.1999.17.8.2341. View

12.

Jung M, Mertens C, Bauer R, Rehwald C, Brune B . Lipocalin-2 and iron trafficking in the tumor microenvironment. Pharmacol Res. 2017; 120:146-156. DOI: 10.1016/j.phrs.2017.03.018. View

13.

Wallace A, Laskowski R, Thornton J . LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995; 8(2):127-34. DOI: 10.1093/protein/8.2.127. View

14.

Brady S, McQuerry J, Qiao Y, Piccolo S, Shrestha G, Jenkins D . Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. Nat Commun. 2018; 9(1):572. PMC: 5799176. DOI: 10.1038/s41467-017-02383-6. View

15.

Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Bengtsson N, Ostenstad B . Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 2000; 35(8):1194-201. DOI: 10.1016/s0959-8049(99)00122-7. View

16.

Goetz D, Willie S, Armen R, Bratt T, Borregaard N, Strong R . Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000; 39(8):1935-41. DOI: 10.1021/bi992215v. View

17.

Vardhini S . In silico evaluation for the potential naturally available drugs for breast cancer. J Recept Signal Transduct Res. 2013; 34(3):174-9. DOI: 10.3109/10799893.2013.868904. View

18.

Singer E, Marko L, Paragas N, Barasch J, Dragun D, Muller D . Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf). 2013; 207(4):663-72. PMC: 3979296. DOI: 10.1111/apha.12054. View

19.

Shi H, Gu Y, Yang J, Xu L, Mi W, Yu W . Lipocalin 2 promotes lung metastasis of murine breast cancer cells. J Exp Clin Cancer Res. 2008; 27:83. PMC: 2614970. DOI: 10.1186/1756-9966-27-83. View

20.

Bonneterre J, Roche H, Monnier A, Guastalla J, Namer M, Fargeot P . Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer. 2002; 87(11):1210-5. PMC: 2408916. DOI: 10.1038/sj.bjc.6600645. View